Wang Qingling, Liu Qingru, Wang Tianyuan, Yang Hongli, Han Zhengjie, Zhang Peng
Department of Pathology, Xuzhou Medical College, Xuzhou, 221004, Jiangsu, China,
Med Oncol. 2015 May;32(5):162. doi: 10.1007/s12032-015-0614-y. Epub 2015 Apr 21.
The endothelial cell protein C receptor (EPCR) has been reported to be involved in the development of several human cancers. However, the role of EPCR in gastric cancer progression has not been clarified. In this study, we show for the first time that EPCR is related to gastric cancer. Our results indicate that EPCR is highly expressed in clinical gastric cancer tissue. Knockdown of EPCR by small interference RNA suppressed the proliferation and migration of MGC803 gastric cancer cells dominantly. Blocking antibodies to protease-activated receptor-1(PAR1) also suppressed the proliferation and migration of MGC803 cells. Knockdown EPCR and blocking PAR1 inhibit activation of extracellular signaling-regulated kinases 1 and 2 (ERK1/2). Taken together, these results indicate that EPCR contributes to the proliferation and migration of MGC803 gastric cancer cells by activating ERK1/2, and this effect of EPCR may be dependent on PAR1. Therefore, EPCR may be act as a novel therapeutic target for inhibiting cell growth in gastric cancer.
据报道,内皮细胞蛋白C受体(EPCR)与多种人类癌症的发生发展有关。然而,EPCR在胃癌进展中的作用尚未阐明。在本研究中,我们首次表明EPCR与胃癌有关。我们的结果表明,EPCR在临床胃癌组织中高表达。通过小干扰RNA敲低EPCR可显著抑制MGC803胃癌细胞的增殖和迁移。蛋白酶激活受体-1(PAR1)阻断抗体也可抑制MGC803细胞的增殖和迁移。敲低EPCR和阻断PAR1可抑制细胞外信号调节激酶1和2(ERK1/2)的激活。综上所述,这些结果表明EPCR通过激活ERK1/2促进MGC803胃癌细胞的增殖和迁移,且EPCR的这种作用可能依赖于PAR1。因此,EPCR可能作为抑制胃癌细胞生长的新型治疗靶点。